Great work by Lorena Saelices Gomez - she/her/hers/ella determining multiple ATTR fibril structures #ISA_2022

Exciting meeting #ISA_2022. The future of diagnostics and therapeutics of Amyloidosis is bright with engagement of all stakeholders. Congratulations to Dr Schonland and ute hegenbart for organizing a very stimulating flawless meeting BU Amyloidosis Center

Home safe after a long day of travel! Thank you Heidelberg for showing your picturesque cobble streets and hospitality. Lots of great science to digest. But first, a morning run to burn off the week's schnitzels and potatoes. Missed you Boston!

1/3:Absolutely need PYP or tissue to start treatment for cardiac #amyloidosis. There are many mimickers by both echo and CMR with variability in quality, technical issues, and interpretation in both, especially outside of amyloid centers.

We're excited to share our report on apoptotic vulnerabilities in AL amyloidosis. We analyzed over 50 primary specimens from AL patients at BU Amyloidosis Center and find that clonal plasma cells are frequently dependent on BCL-2 or MCL-1 for survival. (1/n) nature.com/articles/s4146…

Save the date to hear from four of our incredible BU Amyloidosis Center clinicians during a live webinar hosted by Amyloidosis! Register for Updates in ATTR Cardiac and Neurological Amyloidosis at 12:00 pm ET on Friday, October 28 by visiting pathlms.com/amyloidosis/we…

Daratumumab in AL amyloidosis awechalekar ashpublications.org/blood/article-…

Do not start plasma cell directed therapies till diagnosis of AL Amyloidosis is confirmed by accurate identification of the precursor protein #ASH22 #amyloidosis Dr. Jeffrey Zonder

February is Rare Disease Awareness Month! This month is all about public, medical, & political #amyloidosisawareness. Not only is it critical to let more people know about diagnostics and treatments that already exist but to create momentum for the development of new discoveries.

Avoid implicit bias in amyloidosis & never skip genetic testing, particularly in minority groups. At BU Amyloidosis Center, 7 self-identified white patients with ATTRV122I and 19 self-identified Black patients with ATTRwt. The presentation of amyloidosis is truly diverse! Andrew Staron

Increase awareness, decrease educational gap to diagnose early and improve outcomes. High clinical index of suspicion when red flag symptoms/signs/syndromes present is crucial.

Significant and exciting news! Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201. With this clearance, NEXICART-2 (NCT06097832) is to expand studies of NXC-201 in relapsed/refractory AL amyloidosis to the US. BU Amyloidosis Center nexcella.com/2023/11/21/nex…

While we usually shrug it off as insignificant, the loss of the Y chromosome (mLOY) in men is associated with a much higher cancer mortality, CV mortality and all cause mortality than those without it. Possible association with ATTR amyloidosis. BU Amyloidosis Center

💙Masterclass in Cardiac #Amyloidosis ASNC Society Saurabh Malhotra Lawrence Phillips Day 1⃣⭐️ Prognostic markers in amyloidosis by Andrew Staron Andrew Staron BU Amyloidosis Center 👉ATTR

As the event comes to a close, we want to express our gratitude to our dedicated multidisciplinary team members for sharing their research during the conference. #ISA2024 #Amyloidosis The International Society Of Amyloidosis

Panel discussion - very engaged audience. BU Amyloidosis Center Omar K. Siddiqi, MD, FACC Andrew Staron

Exciting day at U.S. FDA brainstorming prognostic factors and clinical trial endpoints in AL Amyloidosis!

Isabelle Lousada and Kristen Hsu of Amyloidosis Research Consortium kicking off the Amyloidosis Forum at the FDA - accelerating drug development in amyloidosis.